Cardano once made millionaires, and now BlockchainFX ($BFX) aims to repeat history. With $9M raised, CertiK audit, and 4–7% daily rewards, analysts see 100× potential.Cardano once made millionaires, and now BlockchainFX ($BFX) aims to repeat history. With $9M raised, CertiK audit, and 4–7% daily rewards, analysts see 100× potential.

Cardano (ADA) Once Made Millionaires – Now BlockchainFX ($BFX) Presale Is the Top 100x Crypto to Buy in October

For feedback or concerns regarding this content, please contact us at [email protected]
cardano55

100x crypto opportunities have always been the dream that too many skipped when the timing was perfect. Think back to the countless stories of people who ignored Bitcoin under $100, or those who dismissed Ethereum at under $10. October 2025 has already shown us that crypto markets are entering Q4 with massive energy, with top tokens reclaiming dominance and early-stage projects pulling in millions. BlockchainFX ($BFX) has arrived in this moment, giving those who missed earlier chances another shot at a life-changing opportunity.

bfx

BlockchainFX ($BFX) is making headlines with its ongoing presale and ambitious growth plans. While Cardano (ADA) and Ethereum (ETH) continue their runs with consistent updates and strong adoption, participants are buzzing about the potential of $BFX. With its multi-asset trading super app, daily USDT rewards, and revenue-sharing tokenomics, BlockchainFX isn’t just another entry on the list of missed ICO tokens to watch. It is positioning itself as one of the best 100x crypto coins 2025 and a chance to rewrite the regret many people still carry from past missed entries.

Cardano (ADA): The Missed ICO That Changed Lives

Cardano (ADA) was once doubted by critics who called it “too academic” or “too slow” to scale. Those same critics likely regret not joining in when ADA was first introduced during its ICO at around $0.02. Early participants who held tight watched their holdings skyrocket to over $3 at ADA’s peak, multiplying wealth over 100 times. The crypto community saw skeptics turn into silent observers while early adopters walked away with life-changing gains.

That story matters today because it shows how missing a single moment in crypto can define financial futures. ADA crypto news today highlights its long-term sustainability and continuous network upgrades that still excite its community. But while Cardano continues to build, it also reminds everyone of the ICO that minted millionaires. Crypto doesn’t stop offering new chances, and while ADA already had its moonshot moment, other early-stage cryptos with 100x potential are coming forward in Q4 2025.

BlockchainFX ($BFX): A 100x Crypto With Real Utility

BlockchainFX ($BFX) is not just presenting itself as another token to speculate on. This project combines crypto, stocks, forex, and commodities into a single trading super app, which is already pulling in over 10,000 daily users. What sets it apart is the redistribution of up to 70% of trading fees back to holders daily in USDT, allowing participants to earn while holding. This isn’t future talk; the system is already running, rewarding users with 4–7% daily and an annualized APY of up to 90% even during its presale phase.

When people talk about top 100x altcoins, they usually focus on projects with utility that scales. BlockchainFX is exactly that. Beyond passive income, holders gain real-world benefits like BFX Visa cards (Gold, Green, and Metal), enabling crypto spending worldwide. With growing adoption, this project positions itself as not just a token but a tool that could redefine how participants interact with both crypto and traditional markets. That’s why BlockchainFX is already being called one of the missed ICO tokens to watch.

bfx banner

BlockchainFX ($BFX) Presale: The Numbers That Matter

The BlockchainFX presale has already proven its strength. The token price started at $0.01 and has climbed to $0.027, with automatic increases scheduled every Monday, heading toward a $0.05 launch. Over $9 million has been raised from 13,400+ participants, with CertiK audits and KYC compliance adding trust. At the current price, a $50,000 entry would be worth $92,500 at launch, and if $BFX reaches the $1 analyst target, that same entry could grow into nearly $1.85 million.For those joining today, there are added benefits. Using bonus code BLOCK30 gives buyers 30% extra $BFX tokens. Referral rewards mean a 10% commission on purchases from friends, plus leaderboard bonuses for top contributors. The $500,000 giveaway adds another chance to win, with prizes ranging up to $250,000 in tokens. These layers of rewards make BlockchainFX a standout among best 100x crypto coins 2025, not just for potential price appreciation but also for ongoing earning mechanics.

BFX

Conclusion: Is BlockchainFX ($BFX) the Next 100x Crypto?

Crypto history is filled with stories of missed fortunes, from those who ignored Cardano’s ICO to others who sold Ethereum far too early. The question now is whether BlockchainFX ($BFX) will be remembered as the second chance at one of the 100x crypto plays in 2025. With its trading super app, real rewards, and fast-growing presale momentum, the project already shows signs of being one of the top 100x altcoins to enter this October.

The BlockchainFX presale price at $0.027 is still well below the $0.05 launch figure, and the BLOCK30 bonus code lets participants stack 30% more tokens instantly. With referral rewards, Visa card perks, and confirmed exchange listings ahead, this is shaping up to be the best 100x crypto coins 2025 story. Early buyers now have a chance to join before the next price hike, while those who hesitate may look back at October 2025 as the month they let another fortune slip away.

Find Out More Information Here

Website: https://blockchainfx.com/ 

X: https://x.com/BlockchainFXcom

Telegram Chat:https://t.me/blockchainfx_chat

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09